Patents by Inventor David L. G. Nelson

David L. G. Nelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydrobetacarboline compounds
    Patent number: 5886004
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: March 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, David L. G. Nelson
  • Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor mediated conditions
    Patent number: 5736544
    Abstract: The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: April 7, 1998
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Marlene L. Cohen, Jaswant S. Gidda, David L. G. Nelson
  • Method for treating 5HT.sub.2B receptor related conditions
    Patent number: 5688807
    Abstract: The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: November 18, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Marlene L. Cohen, Jaswant S. Gidda, David L. G. Nelson
  • Method of blocking human 5-hydroxytryptamine-2 receptors
    Patent number: 5674875
    Abstract: N-unsubstituted ergolines specifically bind to human 5-HT.sub.2 receptors, and are thus useful in treating diseases such as depression, hypertension and migraine.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: October 7, 1997
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, David L. G. Nelson
  • Thieno[1,5]benzoidiazepine use
    Patent number: 5457101
    Abstract: The compound 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of certain gastrointestinal disorders.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: Beverley Greenwood, David L. G. Nelson